| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KPRXKiora Pharmaceuticals, Inc. | 8.05M | 2.19 | 2.52 | 22.47% | -38.12% | 100% | 0.00 | |
| KALAKALA BIO, Inc. | 16.74M | 0.60 | -0.09 | -141.11% | -388.29% | 2.62 | ||
| CLSDClearside Biomedical, Inc. | 5.81M | 1.11 | -0.16 | -79.77% | -7.81% | |||
| OTLKOutlook Therapeutics, Inc. | 33.47M | 0.52 | -0.29 | -25.93% | ||||
| ADVMAdverum Biotechnologies, Inc. | 96.26M | 4.36 | -0.66 | -72.22% | -130.93% | -189.84% | 1.30 | |
| IRDOpus Genetics, Inc. | 143.45M | 2.08 | -0.97 | -42.3% | -466.09% | -11.43% | ||
| SKYESkye Bioscience, Inc. | 30.87M | 0.96 | -1.32 | -156.01% | 0.01 | |||
| ALDXAldeyra Therapeutics, Inc. | 265.32M | 4.41 | -4.69 | -87.71% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 45K | 0 | 0 | 0 | 6.07M | 6.36M | 11.24M | 3.89M | 0 | 0 |
| Revenue Growth % | -0.9% | -1% | - | - | - | 0.05% | 0.77% | -0.65% | -1% | - |
| Cost of Goods Sold | 0 | 297K | 643K | 955K | 2.01M | 3.17M | 4.1M | 2.56M | 303K | 259K |
| COGS % of Revenue | - | - | - | - | 0.33% | 0.5% | 0.36% | 0.66% | - | - |
| Gross Profit | 45K | -297K | -643K | -955K | 4.07M | 3.19M | 7.14M | 1.33M | -303K | -259K |
| Gross Margin % | 1% | - | - | - | 0.67% | 0.5% | 0.64% | 0.34% | - | - |
| Gross Profit Growth % | - | -7.6% | -1.16% | -0.49% | 5.26% | -0.22% | 1.24% | -0.81% | -1.23% | 0.15% |
| Operating Expenses | 15.99M | 32.67M | 39.88M | 64.72M | 92.29M | 99.42M | 116.58M | 82.69M | 38.85M | 40.17M |
| OpEx % of Revenue | 355.36% | - | - | - | 15.19% | 15.63% | 10.37% | 21.25% | - | - |
| Selling, General & Admin | 4.61M | 7.64M | 10.87M | 35.43M | 65.02M | 81.07M | 105.06M | 65.03M | 20.26M | 18.34M |
| SG&A % of Revenue | 102.42% | - | - | - | 10.7% | 12.74% | 9.35% | 16.71% | - | - |
| Research & Development | 11.38M | 25.03M | 29.01M | 29.29M | 27.27M | 18.35M | 11.52M | 17.65M | 18.59M | 22.09M |
| R&D % of Revenue | 252.93% | - | - | - | 4.49% | 2.88% | 1.02% | 4.54% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -259K |
| Operating Income | -15.95M | -32.67M | -39.88M | -64.72M | -88.22M | -96.23M | -109.43M | -81.36M | -39.15M | -40.98M |
| Operating Margin % | -354.36% | - | - | - | -14.52% | -15.13% | -9.74% | -20.9% | - | - |
| Operating Income Growth % | 0.11% | -1.05% | -0.22% | -0.62% | -0.36% | -0.09% | -0.14% | 0.26% | 0.52% | -0.05% |
| EBITDA | -15.62M | -32.37M | -39.23M | -63.77M | -85.61M | -93.39M | -107.17M | -80.5M | -38.85M | -37.67M |
| EBITDA Margin % | -347.02% | - | - | - | -14.09% | -14.68% | -9.53% | -20.68% | - | - |
| EBITDA Growth % | 0.11% | -1.07% | -0.21% | -0.63% | -0.34% | -0.09% | -0.15% | 0.25% | 0.52% | 0.03% |
| D&A (Non-Cash Add-back) | 330K | 297K | 643K | 955K | 2.62M | 2.84M | 2.27M | 860K | 303K | 3.31M |
| EBIT | -16.08M | -32.4M | -41.19M | -63.42M | -85.87M | -95.74M | -134.22M | -37.56M | -36.38M | -44.29M |
| Net Interest Income | -604K | -620K | -492K | -1.63M | -6.12M | -8.1M | -8.28M | -6.6M | -3.1M | -3.73M |
| Interest Income | 0 | 147K | 527K | 1.69M | 2.36M | 493K | 104K | 664K | 2.71M | 2.06M |
| Interest Expense | 604K | 767K | 1.02M | 3.31M | 8.48M | 8.59M | 8.38M | 7.27M | 5.81M | 5.78M |
| Other Income/Expense | -736K | -498K | -2.34M | -2.02M | -6.12M | -8.1M | -33.17M | 36.53M | -3.05M | 2.47M |
| Pretax Income | -16.68M | -33.17M | -42.21M | -66.74M | -94.35M | -104.33M | -142.6M | -44.82M | -42.2M | -38.51M |
| Pretax Margin % | -370.71% | - | - | - | -15.53% | -16.4% | -12.69% | -11.52% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -16.68M | -33.17M | -42.21M | -66.74M | -94.35M | -104.33M | -142.6M | -44.82M | -42.2M | -38.51M |
| Net Margin % | -370.71% | - | - | - | -15.53% | -16.4% | -12.69% | -11.52% | - | - |
| Net Income Growth % | 0.14% | -0.99% | -0.27% | -0.58% | -0.41% | -0.11% | -0.37% | 0.69% | 0.06% | 0.09% |
| Net Income (Continuing) | -16.68M | -33.17M | -42.21M | -66.74M | -94.35M | -104.33M | -142.6M | -44.82M | -42.2M | -38.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -48.26 | -95.95 | -99.20 | -124.73 | -149.06 | -99.59 | -109.35 | -29.48 | -17.35 | -6.98 |
| EPS Growth % | -0.21% | -0.99% | -0.03% | -0.26% | -0.2% | 0.33% | -0.1% | 0.73% | 0.41% | 0.6% |
| EPS (Basic) | -48.26 | -95.95 | -99.20 | -124.73 | -149.06 | -99.59 | -109.35 | -29.48 | -17.35 | -6.98 |
| Diluted Shares Outstanding | 345.67K | 345.67K | 425.5K | 535.08K | 684.2K | 1.05M | 1.3M | 1.52M | 2.43M | 5.52M |
| Basic Shares Outstanding | 345.67K | 345.67K | 425.5K | 535.08K | 684.2K | 1.05M | 1.3M | 1.52M | 2.43M | 5.52M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.87M | 45.63M | 115.21M | 177.03M | 105.48M | 171.38M | 124.37M | 85.94M | 52.87M | 52.8M |
| Cash & Short-Term Investments | 5.76M | 45.47M | 114.56M | 170.9M | 85.45M | 153.54M | 92.14M | 70.5M | 50.9M | 51.18M |
| Cash Only | 5.76M | 45.47M | 114.56M | 170.9M | 85.45M | 77.26M | 92.14M | 70.5M | 50.9M | 51.18M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 76.28M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 1.03M | 13.1M | 9.85M | 17.45M | 6.5M | 236K | 0 |
| Days Sales Outstanding | - | - | - | - | 787.09 | 565.34 | 566.82 | 609.3 | - | - |
| Inventory | 0 | 0 | 0 | 4.09M | 4.65M | 5.23M | 8.64M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 1.57K | 844.88 | 601.51 | 769.64 | - | - | - |
| Other Current Assets | 43K | 154K | 648K | 477K | 1.38M | 1.55M | 5.22M | 8.25M | 1.06M | 1.62M |
| Total Non-Current Assets | 2.58M | 703K | 920K | 43.94M | 48.84M | 50.23M | 15.06M | 878K | 3.08M | 2.69M |
| Property, Plant & Equipment | 738K | 594K | 786K | 31.73M | 32.48M | 31.02M | 4.02M | 416K | 2.78M | 2.44M |
| Fixed Asset Turnover | 0.06x | - | - | - | 0.19x | 0.21x | 2.80x | 9.36x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 109K | 0 | 134K | 12.21M | 12.58M | 0 | 1.46M | 462K | 301K | 246K |
| Other Non-Current Assets | 1.73M | 109K | 0 | 0 | 3.78M | 19.21M | 9.58M | 0 | 0 | 0 |
| Total Assets | 8.45M | 46.33M | 116.13M | 220.97M | 154.32M | 221.61M | 139.43M | 86.82M | 55.95M | 55.48M |
| Asset Turnover | 0.01x | - | - | - | 0.04x | 0.03x | 0.08x | 0.04x | - | - |
| Asset Growth % | -0.28% | 4.48% | 1.51% | 0.9% | -0.3% | 0.44% | -0.37% | -0.38% | -0.36% | -0.01% |
| Total Current Liabilities | 5.51M | 5.55M | 14.46M | 17.01M | 24.77M | 22.23M | 37.42M | 25.68M | 8.35M | 16.96M |
| Accounts Payable | 1.4M | 997K | 1.2M | 5.45M | 2.52M | 1.72M | 2.78M | 2.35M | 919K | 628K |
| Days Payables Outstanding | - | 1.23K | 682.32 | 2.08K | 457.7 | 198.32 | 247.58 | 334.92 | 1.11K | 885.02 |
| Short-Term Debt | 2M | 556K | 6.67M | 463K | 1.33M | 0 | 711K | 5M | 334K | 10.34M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K | 637K |
| Other Current Liabilities | 1.14M | 1.48M | 3.79M | 5.92M | 13.1M | 9.29M | -1.1M | 10.8M | 2.28M | 2.39M |
| Current Ratio | 1.07x | 8.23x | 7.97x | 10.41x | 4.26x | 7.71x | 3.32x | 3.35x | 6.33x | 3.11x |
| Quick Ratio | 1.07x | 8.23x | 7.97x | 10.17x | 4.07x | 7.48x | 3.09x | 3.35x | 6.33x | 3.11x |
| Cash Conversion Cycle | - | - | - | - | 1.17K | 968.53 | 1.09K | - | - | - |
| Total Non-Current Liabilities | 8.73M | 128.54M | 12M | 98.98M | 99.86M | 99.39M | 85.2M | 42.16M | 40.1M | 26.2M |
| Long-Term Debt | 7.79M | 9.1M | 11.99M | 70.23M | 71.18M | 72.24M | 78.93M | 37.94M | 34.19M | 20.1M |
| Capital Lease Obligations | 0 | 0 | 0 | 28.75M | 28.67M | 27.14M | 548K | 0 | 1.8M | 1.43M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 939K | 119.45M | 9K | 0 | 0 | 0 | 5.72M | 4.22M | 4.11M | 4.66M |
| Total Liabilities | 14.24M | 134.09M | 26.45M | 115.98M | 124.63M | 121.61M | 122.62M | 67.85M | 48.45M | 43.15M |
| Total Debt | 9.79M | 9.65M | 18.65M | 99.44M | 101.18M | 100.92M | 80.19M | 42.95M | 36.32M | 32.25M |
| Net Debt | 4.04M | -35.82M | -95.91M | -71.46M | 15.73M | 23.65M | -11.95M | -27.55M | -14.57M | -18.93M |
| Debt / Equity | - | - | 0.21x | 0.95x | 3.41x | 1.01x | 4.77x | 2.26x | 4.84x | 2.62x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -26.40x | -42.59x | -39.13x | -19.53x | -10.40x | -11.20x | -13.06x | -11.20x | -6.73x | -7.09x |
| Total Equity | -5.79M | -87.76M | 89.68M | 104.99M | 29.69M | 100M | 16.8M | 18.97M | 7.5M | 12.33M |
| Equity Growth % | -2.78% | -14.15% | 2.02% | 0.17% | -0.72% | 2.37% | -0.83% | 0.13% | -0.6% | 0.64% |
| Book Value per Share | -16.76 | -253.89 | 210.76 | 196.21 | 43.40 | 95.46 | 12.89 | 12.48 | 3.09 | 2.23 |
| Total Shareholders' Equity | -5.79M | -87.76M | 89.68M | 104.99M | 29.69M | 100M | 16.8M | 18.97M | 7.5M | 12.33M |
| Common Stock | 6K | 1K | 25K | 34K | 36K | 59K | 66K | 2K | 3K | 6K |
| Retained Earnings | -58.97M | -92.14M | -134.37M | -201.11M | -295.46M | -399.78M | -542.39M | -587.21M | -629.41M | -667.92M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -1.32M | -1.54M | -1.82M | 0 | 4K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.09M | -27.35M | -34.1M | -54.12M | -92.72M | -90.69M | -108.23M | -78.91M | -27.93M | -29.38M |
| Operating CF Margin % | -335.31% | - | - | - | -15.27% | -14.26% | -9.63% | -20.27% | - | - |
| Operating CF Growth % | 0.02% | -0.81% | -0.25% | -0.59% | -0.71% | 0.02% | -0.19% | 0.27% | 0.65% | -0.05% |
| Net Income | -16.68M | -33.17M | -42.21M | -66.74M | -94.35M | -104.33M | -142.6M | -44.82M | -42.2M | -38.51M |
| Depreciation & Amortization | 330K | 297K | 287K | 955K | 843K | 912K | 975K | 537K | 303K | 259K |
| Stock-Based Compensation | 638K | 2.07M | 3.57M | 8.62M | 9.99M | 13.31M | 16.09M | 7.01M | 7.46M | 8.39M |
| Deferred Taxes | 151K | 1.67M | 1.84M | 390K | 0 | -5K | 5.42M | 0 | 0 | 0 |
| Other Non-Cash Items | 134K | 106K | 111K | 274K | 2.73M | 2.99M | 22.51M | -42.12M | -2.39M | 2.26M |
| Working Capital Changes | 340K | 1.68M | 2.3M | 2.38M | -11.94M | -3.57M | -10.62M | 491K | 8.89M | -1.78M |
| Change in Receivables | 36K | 0 | 0 | -157.85M | -11.56M | 1.96M | -5.76M | 15.14M | 78K | 0 |
| Change in Inventory | -571K | 0 | 0 | -3.87M | -4.27M | -2.37M | -6.26M | 1.71M | 7.54M | 0 |
| Change in Payables | 911K | -343K | 205K | 4.09M | -2.77M | -924K | 3.23M | -2.08M | -1.9M | -291K |
| Cash from Investing | -252K | -153K | -480K | -1.58M | -1.33M | -78.21M | 70.8M | 62.72M | -429K | -208K |
| Capital Expenditures | -252K | -153K | -480K | -1.58M | -1.33M | -1.94M | -886K | -313K | -610K | -208K |
| CapEx % of Revenue | 5.6% | - | - | - | 0.22% | 0.31% | 0.08% | 0.08% | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -2.07M | 92K | 114K | 0 | 0 |
| Cash from Financing | 10.48M | 67.21M | 103.7M | 124.1M | 8.98M | 160.63M | 42.55M | -7.94M | 8.51M | 29.88M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 5.48M | 67.21M | 802K | 530K | 587K | 2.1M | 1.58M | 301K | -2M | -42K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -15.34M | -27.5M | -34.58M | -55.7M | -94.06M | -92.64M | -109.12M | -79.22M | -28.54M | -29.59M |
| FCF Margin % | -340.91% | - | - | - | -15.48% | -14.56% | -9.71% | -20.35% | - | - |
| FCF Growth % | 0.02% | -0.79% | -0.26% | -0.61% | -0.69% | 0.02% | -0.18% | 0.27% | 0.64% | -0.04% |
| FCF per Share | -44.38 | -79.56 | -81.26 | -104.10 | -137.47 | -88.43 | -83.68 | -52.10 | -11.73 | -5.36 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.82x | 0.81x | 0.81x | 0.98x | 0.87x | 0.76x | 1.76x | 0.66x | 0.76x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -4403.86% | -68.57% | -140.11% | -160.89% | -244.19% | -250.56% | -318.75% | -388.29% |
| Return on Invested Capital (ROIC) | - | - | - | -355.64% | -167.61% | -85.37% | -127.74% | - | - | - |
| Gross Margin | 100% | - | - | - | 66.94% | 50.13% | 63.55% | 34.22% | - | - |
| Net Margin | -37071.11% | - | - | - | -1553.29% | -1639.85% | -1268.73% | -1151.64% | - | - |
| Debt / Equity | - | - | 0.21x | 0.95x | 3.41x | 1.01x | 4.77x | 2.26x | 4.84x | 2.62x |
| Interest Coverage | -26.40x | -42.59x | -39.13x | -19.53x | -10.40x | -11.20x | -13.06x | -11.20x | -6.73x | -7.09x |
| FCF Conversion | 0.90x | 0.82x | 0.81x | 0.81x | 0.98x | 0.87x | 0.76x | 1.76x | 0.66x | 0.76x |
| Revenue Growth | -90.11% | -100% | - | - | - | 4.74% | 76.67% | -65.37% | -100% | - |
KALA BIO, Inc. (KALA) reported $0.3M in revenue for fiscal year 2024. This represents a 408% increase from $0.1M in 2013.
KALA BIO, Inc. (KALA) grew revenue by 0.0% over the past year. Growth has been modest.
KALA BIO, Inc. (KALA) reported a net loss of $35.8M for fiscal year 2024.
KALA BIO, Inc. (KALA) has a return on equity (ROE) of -388.3%. Negative ROE indicates the company is unprofitable.
KALA BIO, Inc. (KALA) had negative free cash flow of $32.1M in fiscal year 2024, likely due to heavy capital investments.